Teva Pharmaceutical Industries (TEVA) US affiliate and Alvotech (ALVO) said Friday that the Selarsdi injection is now available in the US to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.
Selarsdi is biosimilar to Stelara and it is the second biosimilar now available in the country under the Teva and Alvotech collaboration, they added.
The US Food and Drug Administration provisionally determined that Selarsdi is interchangeable with the reference biologic Stelara after the first interchangeable biosimilar expires, on April 30, the parties said.
Teva Pharmaceutical's stock rose 2.7%, while Alvotech's shares were up 3% in recent Friday premarket activity.
Price: 17.46, Change: +0.46, Percent Change: +2.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。